|
Name |
delta-Guaiene
|
Molecular Formula | C15H24 | |
IUPAC Name* |
(3S,3aS,5R)-3,8-dimethyl-5-prop-1-en-2-yl-1,2,3,3a,4,5,6,7-octahydroazulene
|
|
SMILES |
C[C@H]1CCC2=C(CC[C@H](C[C@@H]12)C(=C)C)C
|
|
InChI |
InChI=1S/C15H24/c1-10(2)13-7-5-11(3)14-8-6-12(4)15(14)9-13/h12-13,15H,1,5-9H2,2-4H3/t12-,13+,15-/m0/s1
|
|
InChIKey |
YHAJBLWYOIUHHM-GUTXKFCHSA-N
|
|
Synonyms |
delta-Guaiene; alpha-Bulnesene; 3691-11-0; (+)-alpha-bulnesene; 2U8L6FYE8U; (3S,3aS,5R)-3,8-dimethyl-5-prop-1-en-2-yl-1,2,3,3a,4,5,6,7-octahydroazulene; (3S,3aS,5R)-3,8-dimethyl-5-(prop-1-en-2-yl)-1,2,3,3a,4,5,6,7-octahydroazulene; .delta.-Guaiene; .alpha.-Bulnesene; .DELTA.-BULNESENE; UNII-2U8L6FYE8U; CHEBI:63447; DTXSID30190387; Azulene, 1,2,3,5,6,7,8,8a-octahydro-1,4-dimethyl-7-(1-methylethenyl)-, (1S,7R,8aS)-; ZINC57986694; C20174; Q27132629; (3R,3AS,5S)-3,8-DIMETHYL-5-PROP-1-EN-2-YL-1,2,3,3A,4,5,6,7-OCTAHYDROAZULENE; Azulene, 1,2,3,5,6,7,8,8a-octahydro-1,4-dimethyl-7-(1-methylethenyl)-, (1S-(1alpha,4alpha,7alpha))-
|
|
CAS | 3691-11-0 | |
PubChem CID | 94275 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 204.35 | ALogp: | 4.6 |
HBD: | 0 | HBA: | 0 |
Rotatable Bonds: | 1 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 0.0 | Aromatic Rings: | 2 |
Heavy Atoms: | 15 | QED Weighted: | 0.518 |
Caco-2 Permeability: | -4.576 | MDCK Permeability: | 0.00001570 |
Pgp-inhibitor: | 0.991 | Pgp-substrate: | 0.003 |
Human Intestinal Absorption (HIA): | 0.003 | 20% Bioavailability (F20%): | 0.912 |
30% Bioavailability (F30%): | 0.005 |
Blood-Brain-Barrier Penetration (BBB): | 0.435 | Plasma Protein Binding (PPB): | 96.65% |
Volume Distribution (VD): | 5.009 | Fu: | 1.87% |
CYP1A2-inhibitor: | 0.665 | CYP1A2-substrate: | 0.731 |
CYP2C19-inhibitor: | 0.317 | CYP2C19-substrate: | 0.768 |
CYP2C9-inhibitor: | 0.308 | CYP2C9-substrate: | 0.662 |
CYP2D6-inhibitor: | 0.02 | CYP2D6-substrate: | 0.753 |
CYP3A4-inhibitor: | 0.412 | CYP3A4-substrate: | 0.316 |
Clearance (CL): | 8.351 | Half-life (T1/2): | 0.1 |
hERG Blockers: | 0.036 | Human Hepatotoxicity (H-HT): | 0.18 |
Drug-inuced Liver Injury (DILI): | 0.748 | AMES Toxicity: | 0.022 |
Rat Oral Acute Toxicity: | 0.02 | Maximum Recommended Daily Dose: | 0.392 |
Skin Sensitization: | 0.66 | Carcinogencity: | 0.662 |
Eye Corrosion: | 0.942 | Eye Irritation: | 0.98 |
Respiratory Toxicity: | 0.301 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC002374 | 0.608 | D0W3OS | 0.235 | ||||
ENC001295 | 0.491 | D04CSZ | 0.228 | ||||
ENC001619 | 0.464 | D04SFH | 0.225 | ||||
ENC000839 | 0.464 | D0I2SD | 0.225 | ||||
ENC000411 | 0.429 | D07BSQ | 0.221 | ||||
ENC003248 | 0.419 | D0F2AK | 0.213 | ||||
ENC003151 | 0.419 | D04GJN | 0.211 | ||||
ENC001924 | 0.390 | D0V2JK | 0.211 | ||||
ENC001832 | 0.390 | D04ATM | 0.209 | ||||
ENC003150 | 0.377 | D0F1UL | 0.207 |